Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML)

Michael W. Schuster, MD, Mikkael A. Sekeres, MD MS, Erick Gamelin, MD PhD, Erik Rasmussen, MS, Gloria Juan, PhD, Abraham Anderson, PhD, Vincent Chow, PhD, Greg Friberg, MD, Florian D. Vogl, MD PhD, Hagop Kantarjian, MD

Blood (2015) 126 (23): 4929.

https://doi.org/10.1182/blood.V126.23.4929.4929

Published: 2015

Journal Articles

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Athanasios Fassas, Klaus Hollmig, Mauricio Pineda-Roman, John Shaughnessy, Joshua Epstein, John Crowley

Blood (2006) 107 (7): 2633–2638.

https://doi.org/10.1182/blood-2005-10-4084

Published: 2006

Journal Articles

Complete Response (CR) with Total Therapy 2 (TT2) for Multiple Myeloma (MM): Low Frequency in Case of Prior MGUS without Adverse Consequences for Survival - Yet Critical for Disease Control in Presumed “De Novo” MM.

Athanasios Fassas, Erik Rasmussen, John Shaughnessy, Guido Tricot, Maurizio Zangari, Frits van Rhee, Elias Anaissie, Klaus Hollmig, Michele Fox, Joshua Epstein, John Crowley, Bart Barlogie

Blood (2005) 106 (11): 1172.

https://doi.org/10.1182/blood.V106.11.1172.1172

Published: 2005

Journal Articles

Gene Expression Profiling of Bulk CD138+ Plasma Cells in Preneoplastic Gammopathy/Asymptomatic Myeloma Identifies Distinct Subsets of Patients.

Madhav V. Dhodapkar, Fenghuang Zhan, Erik Rasmussen, Bart Burington, Brian Durie, John Crowley, Bart Barlogie, John Shaughnessy

Blood (2005) 106 (11): 1218.

https://doi.org/10.1182/blood.V106.11.1218.1218

Published: 2005

Journal Articles

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Ichiro Hanamura, MD, Peter Stewart, PhD, Frederica Cavallo, MD, Bart Burington, MS, Erik Rasmussen, MS, John Crowley, PhD, Fenghuang Zhan, MD, PhD, Yongsheng Huang, MS, Bart Barlogie, MD, PhD, John Shaughnessy, PhD

Blood (2005) 106 (11): 1553.

https://doi.org/10.1182/blood.V106.11.1553.1553

Published: 2005

Journal Articles

Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.

Brian Van Ness, John Crowley, Christine Ramos, Suzanne Grindle, Erik Rasmussen, Emily Blood, Antje Hoering, Bart Barlogie, Philip Greipp, Brian Durie

Blood (2005) 106 (11): 506.

https://doi.org/10.1182/blood.V106.11.506.506

Published: 2005

Journal Articles

Arkansas Autotransplant (AT) Experience with > 2500 Myeloma (MM) Patients: Follow-Up Extending to >15 Years.

Frits van Rhee, Guido Tricot, Elias Anaissie, Maureen Reiner, Maurizio Zangari, Michael Burns, Joshua Epstein, John Shaughnessy, Erik Rasmussen, John Crowley

Blood (2005) 106 (11): 1149.

https://doi.org/10.1182/blood.V106.11.1149.1149

Published: 2005

Journal Articles

Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.

Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Teresa Milner, Joshua Epstein, John Shaughnessy, John Crowley

Blood (2005) 106 (11): 1152.

https://doi.org/10.1182/blood.V106.11.1152.1152

Published: 2005

Journal Articles

Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs “Discontinuous” Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).

Bart Barlogie, Erik Rasmussen, Guido Tricot, Teresa Milner, Elias Anaissie, Frits van Rhee, John Shaughnessy, Joshua Epstein, Klaus Hollmig, Maurizio Zangari, John Crowley

Blood (2005) 106 (11): 1153.

https://doi.org/10.1182/blood.V106.11.1153.1153

Published: 2005

Journal Articles

Total Therapy 3 (TT3) Incorporating Velcade R (V) Intro Upfront Management of Multiple Myeloma (MM): Comparison with TT2 + Thalidomide (T).

Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Joshua Epstein, John Shaughnessy, John Crowley

Blood (2005) 106 (11): 1154.

https://doi.org/10.1182/blood.V106.11.1154.1154

Published: 2005

Journal Articles

Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse.

Bart Barlogie, Ichiro Hanamura, Bart Burington, Erik Rasmussen, Peter Stewart, Guido Tricot, Elias Anaissie, Maurizio Zangari, Frits van Rhee, Klaus Hollmig, Teresa Milner, Joshua Epstein, John Crowley, John Shaughnessy

Blood (2005) 106 (11): 1155.

https://doi.org/10.1182/blood.V106.11.1155.1155

Published: 2005

Journal Articles

Prognosis in Multiple Myeloma (MM): Characterization of “Losers” (L) in Good Risk and “Winners” (W) in High Risk Disease.

Elias Anaissie, Erik Rasmussen, John Shaughnessy, Guido Tricot, Bart Barlogie

Blood (2005) 106 (11): 1161.

https://doi.org/10.1182/blood.V106.11.1161.1161

Published: 2005

Journal Articles

SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure.

Brian G. Van Ness, John C. Crowley, Christine Ramos, Suzanne Grindle, Erik Rasmussen, Antje Hoering, Philip Greipp, Bart Barlogie, Brian Durie

Blood (2005) 106 (11): 3488.

https://doi.org/10.1182/blood.V106.11.3488.3488

Published: 2005

Journal Articles

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Brian Van Ness, John Crowley, Emily Blood, Erik Rasmussen, Christine Ramos, Suzanne Grindle, Gareth Morgan, David Johnson, Antje Hoering, Philip Greipp, Bart Barlogie, Brian Durie

Blood (2005) 106 (11): 3489.

https://doi.org/10.1182/blood.V106.11.3489.3489

Published: 2005

Journal Articles

Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3).

Federica Cavallo, Erik Rasmussen, Maurizio Zangari, Guido Tricot, Belinda Fender, Michelle Fox, Michael Burns, Bart Barlogie

Blood (2005) 106 (11): 3490.

https://doi.org/10.1182/blood.V106.11.3490.3490

Published: 2005

Journal Articles

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Ronald Walker, MD, Erik Rasmussen, MS, Federica Cavallo, MD, Laurie Jones-Jackson, MD, Elias Anaissie, MD, Terri Alpe, BS, Joshua Epstein, DSc, Frits Van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 3493.

https://doi.org/10.1182/blood.V106.11.3493.3493

Published: 2005

Journal Articles

Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.

Radek Spisek, Lyn-Chi Chen, Matthew Scanlan, Andrew Simpson, Gerd Ritter, Erik Rasmussen, Jason McCoy, Anne Murray, Joseph Krasovsky, Brian Durie, John Crowley, Amitabha Mazumder, Sundar Jagannath, Bart Barlogie, Ali Gure, Madhav Dhodapkar

Blood (2005) 106 (11): 5116.

https://doi.org/10.1182/blood.V106.11.5116.5116

Published: 2005

Journal Articles

Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.

Ronald Walker, MD, Erik Rasmussen, MS, Laurie Jones-Jackson, MD, Elias J. Anaissie, MD, Terri L. Alpe, BS, Joshua Epstein, DSc, Frits Van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD.

Blood (2005) 106 (11): 5079.

https://doi.org/10.1182/blood.V106.11.5079.5079

Published: 2005

Journal Articles

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.

Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Lisa Jackson, Joshua Epstein, John Shaughnessy, John Crowley, Bart Barlogie

Blood (2005) 106 (11): 423.

https://doi.org/10.1182/blood.V106.11.423.423

Published: 2005

Journal Articles

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628

Madhav V. Dhodapkar, Mohamad A. Hussein, Erik Rasmussen, Alan Solomon, Richard A. Larson, John J. Crowley, Bart Barlogie

Blood (2004) 104 (12): 3520–3526.

https://doi.org/10.1182/blood-2004-05-1924

Published: 2004

NARROW

Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML)

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

Complete Response (CR) with Total Therapy 2 (TT2) for Multiple Myeloma (MM): Low Frequency in Case of Prior MGUS without Adverse Consequences for Survival - Yet Critical for Disease Control in Presumed “De Novo” MM.

Gene Expression Profiling of Bulk CD138+ Plasma Cells in Preneoplastic Gammopathy/Asymptomatic Myeloma Identifies Distinct Subsets of Patients.

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Incidence, Outcomes, and SNP Genotypes Show Different Ethnic Association in Patients with Myeloma, Assessed in SWOG and ECOG Clinical Trials S9321 and E9486: From the Bank on a Cure.

Arkansas Autotransplant (AT) Experience with > 2500 Myeloma (MM) Patients: Follow-Up Extending to >15 Years.

Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.

Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs “Discontinuous” Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM).

Total Therapy 3 (TT3) Incorporating Velcade R (V) Intro Upfront Management of Multiple Myeloma (MM): Comparison with TT2 + Thalidomide (T).

Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse.

Prognosis in Multiple Myeloma (MM): Characterization of “Losers” (L) in Good Risk and “Winners” (W) in High Risk Disease.

SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure.

SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.

Serum Free-Lite Chain (sFLC) Assay in Multiple Myeloma (MM): Clinical Correlates and Prognostic Implications in Newly Diagnosed MM Patients Treated with Total Therapy 2 or 3 (TT2/3).

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Differential Antigenic Targets of Anti-Tumor Immune Response and Selective Immunity to Stem Cell Associated Group B SOX Proteins in Preneoplastic Versus Malignant Gammopathy.

Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only